236 related articles for article (PubMed ID: 33452858)
1. Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity.
Kulkarni-Munje A; Palkar S; Shrivastava S; Lalwani S; Mishra AC; Arankalle VA
Immun Inflamm Dis; 2021 Jun; 9(2):419-434. PubMed ID: 33452858
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Immune Profiling Reveals CD56
Dutt TS; LaVergne SM; Webb TL; Baxter BA; Stromberg S; McFann K; Berry K; Tipton M; Alnachoukati O; Zier L; Ebel G; Dunn J; Henao-Tamayo M; Ryan EP
J Immunol; 2022 Feb; 208(3):685-696. PubMed ID: 34987111
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte Subset Alteration and Monocyte CD4 Expression Reduction in Patients with Severe COVID-19.
Kazancioglu S; Yilmaz FM; Bastug A; Sakallı A; Ozbay BO; Buyuktarakci C; Bodur H; Yilmaz G
Viral Immunol; 2021 Jun; 34(5):342-351. PubMed ID: 33264073
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infection induces mixed M1/M2 phenotype in circulating monocytes and alterations in both dendritic cell and monocyte subsets.
Matic S; Popovic S; Djurdjevic P; Todorovic D; Djordjevic N; Mijailovic Z; Sazdanovic P; Milovanovic D; Ruzic Zecevic D; Petrovic M; Sazdanovic M; Zornic N; Vukicevic V; Petrovic I; Matic S; Karic Vukicevic M; Baskic D
PLoS One; 2020; 15(12):e0241097. PubMed ID: 33382687
[TBL] [Abstract][Full Text] [Related]
5. The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes.
Tang G; Huang M; Luo Y; Liu W; Lin Q; Mao L; Wu S; Xiong Z; Hou H; Sun Z; Wang F
Front Immunol; 2021; 12():697622. PubMed ID: 34777333
[TBL] [Abstract][Full Text] [Related]
6. Long-term infection of SARS-CoV-2 changed the body's immune status.
Lin L; Luo S; Qin R; Yang M; Wang X; Yang Q; Zhang Y; Wang Q; Zhu R; Fan H; Wang H; Hu Y; Wang L; Hu D
Clin Immunol; 2020 Sep; 218():108524. PubMed ID: 32659373
[TBL] [Abstract][Full Text] [Related]
7. Antigen-Specific CD4
Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
Front Immunol; 2022; 13():827048. PubMed ID: 35237272
[TBL] [Abstract][Full Text] [Related]
8. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.
Carsetti R; Zaffina S; Piano Mortari E; Terreri S; Corrente F; Capponi C; Palomba P; Mirabella M; Cascioli S; Palange P; Cuccaro I; Milito C; Zumla A; Maeurer M; Camisa V; Vinci MR; Santoro A; Cimini E; Marchioni L; Nicastri E; Palmieri F; Agrati C; Ippolito G; Porzio O; Concato C; Onetti Muda A; Raponi M; Quintarelli C; Quinti I; Locatelli F
Front Immunol; 2020; 11():610300. PubMed ID: 33391280
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.
Nielsen SS; Vibholm LK; Monrad I; Olesen R; Frattari GS; Pahus MH; Højen JF; Gunst JD; Erikstrup C; Holleufer A; Hartmann R; Østergaard L; Søgaard OS; Schleimann MH; Tolstrup M
EBioMedicine; 2021 Jun; 68():103410. PubMed ID: 34098342
[TBL] [Abstract][Full Text] [Related]
10. Identification of SARS-CoV-2-specific immune alterations in acutely ill patients.
Rébillard RM; Charabati M; Grasmuck C; Filali-Mouhim A; Tastet O; Brassard N; Daigneault A; Bourbonnière L; Anand SP; Balthazard R; Beaudoin-Bussières G; Gasser R; Benlarbi M; Moratalla AC; Solorio YC; Boutin M; Farzam-Kia N; Descôteaux-Dinelle J; Fournier AP; Gowing E; Laumaea A; Jamann H; Lahav B; Goyette G; Lemaître F; Mamane VH; Prévost J; Richard J; Thai K; Cailhier JF; Chomont N; Finzi A; Chassé M; Durand M; Arbour N; Kaufmann DE; Prat A; Larochelle C
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33635833
[TBL] [Abstract][Full Text] [Related]
11. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
[TBL] [Abstract][Full Text] [Related]
12. Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.
Vo HTM; Maestri A; Auerswald H; Sorn S; Lay S; Seng H; Sann S; Ya N; Pean P; Dussart P; Schwartz O; Ly S; Bruel T; Ly S; Duong V; Karlsson EA; Cantaert T
Front Immunol; 2022; 13():817905. PubMed ID: 35185909
[TBL] [Abstract][Full Text] [Related]
13. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
Front Immunol; 2021; 12():684014. PubMed ID: 34194438
[TBL] [Abstract][Full Text] [Related]
14. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens.
Uraki R; Imai M; Ito M; Shime H; Odanaka M; Okuda M; Kawaoka Y; Yamazaki S
PLoS Pathog; 2021 Dec; 17(12):e1010085. PubMed ID: 34882757
[TBL] [Abstract][Full Text] [Related]
15. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
Front Immunol; 2021; 12():700921. PubMed ID: 34539631
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of lymphocyte subpopulations in the peripheral blood of patients with COVID-19: Implications for disease severity and prognosis.
Xu X; Huang J; Zhang H; Lu W; Liu J
Immun Inflamm Dis; 2024 May; 12(5):e1281. PubMed ID: 38780019
[TBL] [Abstract][Full Text] [Related]
17. T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.
Zenarruzabeitia O; Astarloa-Pando G; Terrén I; Orrantia A; Pérez-Garay R; Seijas-Betolaza I; Nieto-Arana J; Imaz-Ayo N; Pérez-Fernández S; Arana-Arri E; Borrego F
Front Immunol; 2021; 12():655934. PubMed ID: 33777054
[TBL] [Abstract][Full Text] [Related]
18. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19.
Schub D; Klemis V; Schneitler S; Mihm J; Lepper PM; Wilkens H; Bals R; Eichler H; Gärtner BC; Becker SL; Sester U; Sester M; Schmidt T
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32937615
[TBL] [Abstract][Full Text] [Related]
19. Immune cell profiling and antibody responses in patients with COVID-19.
Rezaei M; Mahmoudi S; Mortaz E; Marjani M
BMC Infect Dis; 2021 Jul; 21(1):646. PubMed ID: 34225645
[TBL] [Abstract][Full Text] [Related]
20. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
